Conditions: Malignant Neoplasm Interventions: Drug: TSN084 Sponsors: Tyligand Bioscience (Shanghai) Limited Recruiting (Source: ClinicalTrials.gov)

Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Interventions: Drug: RC48; Drug: Adebrelimab; Drug: Apatinib; Drug: S-1 Sponsors: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)

Conditions: Hematological Malignancies Interventions: Drug: HMPL-506 Sponsors: Hutchmed Not yet recruiting (Source: ClinicalTrials.gov)

Conditions: Esophageal Cancer Interventions: Drug: neoadjuvant anti-PD-1; Drug: neoadjuvant anti-PD-1 with LDRT Sponsors: Shanghai Chest Hospital Not yet recruiting (Source: ClinicalTrials.gov)

Conditions: Endometrial Cancer Interventions: Drug: Lurbinectedin; Drug: Dostarlimab Sponsors: Vall d'Hebron Institute of Oncology Not yet recruiting (Source: ClinicalTrials.gov)MedWorm Message:

Conditions: Unresectable Breast Cancer; Metastatic Breast Cancer; HER2-low Expressing Breast Cancer; HER2-positive Breast Cancer Interventions: Drug: Trastuzumab deruxtecan Sponsors: AstraZeneca; Daiichi Sankyo Not yet recruiting (Source: ClinicalTrials.gov)